Efficacy and safety of apheresis therapy in AQP 4 antibody‐positive NMOSD attack: A propensity score‐matched cohort study
CNS Neuroscience & Therapeutics · 2024-05 · 30 (5)
DOI: 10.1111/cns.14780 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 24.05.2024. Verfasst von Yun Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Neuromyelitis Optica, Propensity Score, Aquaporin 4, Blood Component Removal. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Natural Science Foundation grant.
Abstract (Originalsprache)
Objective
Plasma exchange (PE) and immunoadsorption (IA) are recognized as effective ways to treat attacks in AQP4 antibody‐positive NMOSD, but high‐quality evidence was lacking. To evaluate the efficacy and safety of PE/IA plus intravenous methylprednisolone (IVMP) in NMOSD attacks using propensity scores to match IVMP as control.
Methods
Patients were from a prospective observational cohort study. Stratification and interval propensity score matching (PSM) were used to reduce selection bias by matching baseline characteristics (gender, age, time to IVMP, EDSS at attack) between PE/IA + IVMP and IVMP group (in a ratio of 1:2). The primary endpoint of efficacy was EDSS change at 6 months. Adverse events and changes in laboratory tests were recorded.
Results
Four hundred and eleven attacks of 336 patients were screened for PSM, and 90 attacks (30 PE/IA + IVMP and 60 IVMP) were included in the analysis. There were significant differences in EDSS [6.25 vs. 6.75; IQR (4.50–8.38 vs. 5.00–8.00), p = 0.671] and visual acuity [median logMAR = 0.35 vs. 1.00; IQR (0.30–0.84 vs. 0.95–1.96), p = 0.002] change between two groups at 6 months. PE/IA + IVMP treatment demonstrated predictive capacity for good recovery as indicated by an area under the curve (AUC) of 0.726. Fibrinogen reduction was found during PE/IA + IVMP treatment [ n = 15 (50.00%)], but no severe adverse events led to apheresis treatment discontinuation.
Discussion
After PSM analysis, IVMP+PE/IA in acute attack of NMOSD achieved better and continuous improvement in neurological function within 6 months compared with IVMP alone. PE/IA treatment showed a good safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- China National Clinical Research Center for Neurological Diseases, Beijing, China.
ORCID-Profile: Yun Xu, De-Cai Tian
Förderung
- National Natural Science Foundation of China
- Beijing Natural Science Foundation grant
Zitieren
APA
Xu, Y., Wang, H., Song, T., Yin, L., Yao, Y., Wei, Y., Cong, H., Sun, J., Zhang, X., & Tian, D. C. (2024). Efficacy and safety of apheresis therapy in AQP 4 antibody‐positive NMOSD attack: A propensity score‐matched cohort study. CNS Neuroscience & Therapeutics, 30(5). https://doi.org/10.1111/cns.14780
Vancouver
Xu Y, Wang H, Song T, Yin L, Yao Y, Wei Y, et al. Efficacy and safety of apheresis therapy in AQP 4 antibody‐positive NMOSD attack: A propensity score‐matched cohort study. CNS Neuroscience & Therapeutics. 2024;30(5). doi:10.1111/cns.14780
BibTeX
@article{Xu2024,
author = {Xu, Yun and Wang, Huabing and Song, Tian and Yin, Linlin and Yao, Yajun and Wei, Yuzhen and Cong, Hengri and Sun, Jiali and Zhang, Xinghu and Tian, De-Cai},
title = {Efficacy and safety of apheresis therapy in AQP 4 antibody‐positive NMOSD attack: A propensity score‐matched cohort study},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
volume = {30},
number = {5},
doi = {10.1111/cns.14780}
}
EUVIMED